Type 2 Diabetes Trial, Not Yet Recruiting NCT07639684 Sponsor: Boston Scientific Corporation Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Not Yet Recruiting

NCT07639684
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • The person must be willing and able to give written consent to take part in the study.
  • The person must be 22 years of age or older.
  • The person must have a body mass index (BMI) between 30 and 50 kg/m².
  • The person must have an HbA1c (a blood sugar level measured over time) between 7.5% and 10.5%.
  • The person must have Type 2 Diabetes currently managed with a specific type of diabetes medication called a GLP-1 or GLP-1/GIP medication, at the highest dose they can tolerate for at least 6 months, with or without other diabetes tablets, and their doctor must be planning to start them on insulin.
  • The person's weight must have been stable (changed by less than 5% of total body weight) in the 3 months before the screening visit.
  • The person must meet the medical requirements for a specific weight loss stomach procedure using a device called the OverStitch™ or OverStitch NXT™ system (confirm with trial site).
  • The person must have declined or been found unsuitable for metabolic or bariatric (weight loss) surgery.
  • The person must agree not to use any weight loss treatments or supplements outside of the study's lifestyle program for one year after the procedure.
  • The person must be willing and able to follow the study schedule, including the lifestyle program and all required visits.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People currently using insulin to manage their diabetes (previous short-term insulin use during pregnancy or for up to one month during a serious illness may be acceptable — confirm with trial site).
  • People who have not been following their prescribed diabetes medication routine consistently.
  • People who have had episodes of reactive or severe low blood sugar within the past year.
  • People who have experienced diabetic ketoacidosis or a condition called hyperosmolar nonketotic coma within the past year.
  • People with any known conditions that affect weight loss or blood sugar control.
  • People taking long-term steroid or immune-suppressing medications at the time of joining, or who are likely to need them during the study.
  • People with moderate-to-advanced kidney disease, defined as an eGFR (a measure of kidney function) below 60 mL/min.
  • People with ongoing low red blood cell levels (anaemia), specifically a haemoglobin level below 10 g/dL.
  • People who drink alcohol at levels considered "heavy drinking" based on guidelines for their sex.
  • People who have used prescription or over-the-counter weight loss medications or supplements in the three months before screening, or who plan to use any during the study.
  • People whom the trial doctor does not consider suitable for the stomach procedure, based on medical, psychological, or nutritional assessments done in the past 12 months.
  • People who are currently pregnant, planning to become pregnant, or breastfeeding within the year following the procedure.
  • People considered to be vulnerable subjects (confirm with trial site).
  • People who are currently taking part in, or planning to join, another clinical study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ildiko Lingvay, MD, UT Southwestern

Phone: 781-305-0506

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Boston Scientific Corporation
Registry
ClinicalTrials.gov
Start date
1 February 2027
Est. completion
1 May 2029

Primary endpoints

Serious Adverse Events; Average Change in HbA1c

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov